CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay

Drug Metabolism and Disposition

Volumn 39, Issue 5, 2011, Pages 838-846

  Iwamura, Atsushi ^a   Fukami, Tatsuki ^a   Hosomi, Hiroko ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BENZBROMARONE; CANDESARTAN; CYTOCHROME P450 2C9; DICLOFENAC 4' HYDROXYLASE; EPROSARTAN; FLUINDOSTATIN; FLUTAMIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; OXYGENASE; SEMICARBAZIDE; TELMISARTAN; TERBINAFINE; TIENILIC ACID; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; VALPROIC ACID; VALSARTAN; ZOLPIDEM;

ARTICLE; CELL STRAIN HEK293; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY TEST; DNA ADDUCT; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; METABOLIC ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY;

ANTIHYPERTENSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZBROMARONE; BIOTRANSFORMATION; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; HEK293 CELLS; HEP G2 CELLS; HEPATOCYTES; HUMANS; LOSARTAN; NF-E2-RELATED FACTOR 2; SEMICARBAZIDES; SENSITIVITY AND SPECIFICITY; TIME FACTORS; URICOSURIC AGENTS;

ADENOVIRIDAE;

EID: 79954991439     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037259     Document Type: Article

References (40)

1. Baillie TA (1988) Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem Res Toxicol 1:195-199.
2. Bonierbale E, Valadon P, Pons C, Desfosses B, Dansette PM, and Mansuy D (1999) Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: Use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds. Chem Res Toxicol 12:286-296. (Pubitemid 29136456)
3. Bosch X (1997) Losartan-induced hepatotoxicity. JAMA 278:1572.
4. Chang CY and Schiano TD (2007) Review article: Drug hepatotoxicity. Aliment Pharmacol Ther 25:1135-1151. (Pubitemid 46650295)
5. Chauret N, Nicoll-Griffith D, Friesen R, Li C, Trimble L, Dubí D, Fortin R, Girard Y, and Yergey J (1995) Microsomal metabolism of the 5-lipoxygenase inhibitors L-746,530 and L-739,010 to reactive intermediates that covalently bind to protein: The role of the 6,8- dioxabicyclo[3.2.1]octanyl moiety. Drug Metab Dispos 23:1325-1334. (Pubitemid 26009693)
6. Copple IM, Goldring CE, Kitteringham NR, and Park BK (2008) The Nrf2-Keap1 defence pathway: Role in protection against drug-induced toxicity. Toxicology 246:24-33.
7. Edwards RJ, Adams DA, Watts PS, Davies DS, and Boobis AR (1998) Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 56:377-387. (Pubitemid 28473214)
8. Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, Harada T, and Yamamoto M (2001) High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 59:169-177. (Pubitemid 32117993)
9. Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, and Robinson WT (1999) The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 27:410-416. (Pubitemid 29114251)
10. Gan J, Ruan Q, He B, Zhu M, Shyu WC, and Humphreys WG (2009) In vitro screening of 50 highly prescribed drugs for thiol adduct formation-comparison of potential for drug-induced toxicity and extent of adduct formation. Chem Res Toxicol 22:690-698.
11. Goda R, Nagai D, Akiyama Y, Nishikawa K, Ikemoto I, Aizawa Y, Nagata K, and Yamazoe Y (2006) Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)- phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. Drug Metab Dispos 34:828-835.
12. Greer ML, Barber J, Eakins J, and Kenna JG (2010) Cell based approaches for evaluation of drug-induced liver injury. Toxicology 268:125-131.
13. Guengerich FP (2008) Cytochrome P450 and chemical toxicology. Chem Res Toxicol 21:70-83. (Pubitemid 351219709)
14. Hewitt NJ and Hewitt P (2004) Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 34:243-256. (Pubitemid 38478893)
15. Hosomi H, Akai S, Minami K, Yoshikawa Y, Fukami T, Nakajima M, and Yokoi T (2010) An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and γ-glutamylcysteine synthetase knockdown cells. Toxicol In Vitro 24:1032-1038.
16. Iverson SL and Uetrecht JP (2001) Identification of a reactive metabolite of terbinafine: Insights into terbinafine-induced hepatotoxicity. Chem Res Toxicol 14:175-181. (Pubitemid 32173319)
17. Karsenti D, Blanc P, Bacq Y, and Metman EH (1999) Hepatotoxicity associated with zolpidem treatment. BMJ 318:1179. (Pubitemid 29201573)
18. Kassahun K, Farrell K, and Abbott F (1991) Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab Dispos 19:525-535.
19. Koenigs LL, Peter RM, Hunter AP, Haining RL, Rettie AE, Friedberg T, Pritchard MP, Shou M, Rushmore TH, and Trager WF (1999) Electrospray ionization mass spectrometric analysis of intact cytochrome P450: Identification of tienilic acid adducts to P450 2C9. Biochemistry 38:2312-2319.
20. Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474-485. (Pubitemid 36910027)
21. Leone AM, Kao LM, McMillian MK, Nie AY, Parker JB, Kelley MF, Usuki E, Parkinson A, Lord PG, and Johnson MD (2007) Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. Chem Res Toxicol 20:600-608. (Pubitemid 46762094)
22. Li AP (2002) A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 142:7-23. (Pubitemid 35232550)
23. Lu SC (1999) Regulation of hepatic glutathione synthesis: Current concepts and controversies. FASEB J 13:1169-1183. (Pubitemid 29300363)
24. McDonald MG and Rettie AE (2007) Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: Formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol 20:1833-1842.
25. Mizuno K, Katoh M, Okumura H, Nakagawa N, Negishi T, Hashizume T, Nakajima M, and Yokoi T (2009) Metabolic activation of benzodiazepines by CYP3A4. Drug Metab Dispos 37:345-351.
26. Nishiya T, Kato M, Suzuki T, Maru C, Kataoka H, Hattori C, Mori K, Jindo T, Tanaka Y, and Manabe S (2008) Involvement of cytochrome P450-mediated metabolism in tienilic acid hepatotoxicity in rats. Toxicol Lett 183:81-89.
27. O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, Gao B, Kaludercic N, Angeline A, Bernardi P, et al. (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80:580-604. (Pubitemid 44214526)
28. Ohbuchi M, Miyata M, Nagai D, Shimada M, Yoshinari K, and Yamazoe Y (2009) Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity. Drug Metab Dispos 37:97-105.
29. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, and Williams DP (2005) The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 45:177-202. (Pubitemid 40261802)
30. Rodríguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell JV, and Gómez- Lechón MJ (2002) Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: Molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32:505-520.
31. Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, and Rettie AE (1997) Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 283:698-703. (Pubitemid 27514629)
32. Stearns RA, Chakravarty PK, Chen R, and Chiu SH (1995) Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 23:207-215.
33. Tabak F, Mert A, Ozaras R, Biyikli M, Ozturk R, Ozbay G, Senturk H, and Aktuglu Y (2002) Losartan-induced hepatic injury. J Clin Gastroenterol 34:585-586. (Pubitemid 34429424)
34. Tang W, Borel AG, Fujimiya T, and Abbott FS (1995) Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: Hepatic microvesicular steatosis and glutathione status. Chem Res Toxicol 8:671-682.
35. Thole Z, Manso G, Salgueiro E, Revuelta P, and Hidalgo A (2004) Hepatotoxicity induced by antiandrogens: A review of the literature. Urol Int 73:289-295. (Pubitemid 39664297)
36. Usui T, Mise M, Hashizume T, Yabuki M, and Komuro S (2009) Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab Dispos 37:2383-2392.
37. Vickers AE, Sinclair JR, Zollinger M, Heitz F, Glänzel U, Johanson L, and Fischer V (1999) Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos 27:1029-1038. (Pubitemid 29409639)
38. Vignati L, Turlizzi E, Monaci S, Grossi P, Kanter R, and Monshouwer M (2005) An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 216:154-167. (Pubitemid 41712005)
39. Von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, and Shader RI (1999) Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 48:89-97. (Pubitemid 29296668)
40. Yoshikawa Y, Hosomi H, Fukami T, Nakajima M, and Yokoi T (2009) Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity. Toxicol In Vitro 23:1179-1187.